CSTONE PHARMA-B (02616) saw its shares rise more than 8% in late trading. At the time of writing, the stock was up 6.73%, trading at HK$6.66, with a turnover of HK$93.123 million. The move follows the company's announcement that its drug sugemalimab has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for a new indication. The approval covers the use of sugemalimab as a monotherapy for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, who do not have EGFR sensitizing mutations or ALK or ROS1 genomic alterations, and whose disease has not progressed following platinum-based chemoradiotherapy (CRT). Ping An Securities issued a research note stating that CSTONE PHARMA-B uses clinical development as its engine, with commercial products from its R&D 1.0 phase providing reliable cash flow. The company's R&D 2.0 phase involves innovative pipeline and cutting-edge technology layouts, with core candidates already entering the clinical trial stage and further projects expected to advance into clinical development. The securities firm forecasts the company will achieve revenues of 195 million yuan, 464 million yuan, and 633 million yuan for 2025, 2026, and 2027, respectively, initiating coverage with a "recommend" rating.